- Home
- PETZ vs SILO Comparison
PETZ vs SILO Comparison
Compare PETZ & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETZ | SILO |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Apparel |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 8.0M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | PETZ | SILO |
|---|---|---|
| Price | $1.04 | $0.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.5K | ★ 141.3K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $1,046,006.00 | $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.39 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.65 | $0.36 |
| 52 Week High | $1.68 | $3.37 |
Technical Indicators
Market Signals| Indicator | PETZ | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 47.91 | 44.64 |
| Support Level | $1.01 | $0.45 |
| Resistance Level | $1.08 | $0.48 |
| Average True Range (ATR) | 0.04 | 0.03 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 46.15 | 77.68 |
Price Performance
Historical ComparisonAbout PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.